Status:
COMPLETED
Efficay and Safety of Empagliflozin Versus Sitagliptin for the In-patient Management of Hyperglycemia
Lead Sponsor:
Medanta, The Medicity, India
Collaborating Sponsors:
Diabetes & Endocrinology Foundation
Conditions:
Type 2 Diabetes
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Clinical guidelines from professional organizations have recommended the use of multidose insulin regimens as the preferred therapy for glycaemic control in patients admitted to hospital in a non-inte...
Detailed Description
The management of hyperglycemia in noncritically ill, hospitalized patients with diabetes mellitus is mainly based on insulin therapy . This usually consists of one dose of long-acting basal insulin a...
Eligibility Criteria
Inclusion
- Patients aged 18-years and above with type 2 diabetes and a random blood glucose concentration of 140-400 mg/dL who were being treated with diet or oral antidiabetic drugs or had a total daily insulin dose of 0•6 units per kg or less, admitted to general medicine or surgery
Exclusion
- Patients with a blood glucose concentration greater than 400mg/dL or with current or previous history of diabetic ketoacidosis,
- Type 1 diabetes,
- Hyperglycaemia without a known history of diabetes
- Patients expected to be without oral intake for more than 48 h
- Patients admitted to or expected to require admission to an intensive care unit
- Clinically relevant hepatic disease or impaired renal function \[eGFR\] \<30 mL/min per 1•73 m²)
- Pregnancy, and any mental health condition rendering the patient unable to give informed consent
- Current or recurrent uti(more than 2 times in last 6 months)
Key Trial Info
Start Date :
January 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2025
Estimated Enrollment :
220 Patients enrolled
Trial Details
Trial ID
NCT06187285
Start Date
January 1 2024
End Date
June 1 2025
Last Update
June 13 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Division Of Endocrinology & Diabetes, Medanta The Medicity
Gurgaon, Haryana, India, 122001